Helaina, a maker of human-equivalent bioactive proteins such as lactoferrin, has raised a $45 million Series B, CEO Laura Katz tells Axios exclusively.
Why it matters: The market for lactoferrin is expected to grow due to its anti-inflammatory, antibacterial and antiviral properties.
